Crucible Moments: Natera ft. Matthew Rabinowitz - A Personal Mission That Led to a Biotech Revolution

Podcast Information:

• Title: Crucible Moments
• Host: Roelof Botha, Sequoia Capital
• Episode: Natera ft. Matthew Rabinowitz
• Release Date: November 21, 2024
• Description: This episode delves into the pivotal decisions and challenges that shaped Natera, a leader in genetic testing for women's health, oncology, and organ transplant rejection. Featuring insights from co-founder Matthew Rabinowitz and key team members, the discussion highlights the company's mission-driven journey from its inception to becoming a multi-billion-dollar enterprise.

1. Introduction to Natera and Its Origins

Host Roelof Botha introduces Natera as a global leader in genetic testing, emphasizing its significant impact:

"40% of all pregnancies in the United States are tested using Natera technology to ensure the health of the child. And nearly half of oncologists in America have ordered Natera's cancer screening test." [00:23]

Natera's inception is traced back to Matthew Rabinowitz, who, driven by personal tragedy and a passion for solving complex genetic problems, transitioned from electrical engineering to biotechnology.

2. The Personal Mission Behind Natera

Matthew Rabinowitz shares the emotional catalyst for founding Natera:

"In 2003. My sister had a kid with Down syndrome. The baby was born... the child died after six days. I couldn't understand how... none of that technology had found its way into diagnostics." [02:32]

This loss ignited his mission to apply advanced signal processing techniques to genetics, aiming to revolutionize diagnostic testing.

3. Early Challenges and Technological Innovations

Natera's initial focus was on improving genetic data computation and integrating it with clinical data. Jonathan Sheena, co-founder, highlights the infancy of genetics at the time:

"Geneticists needed help understanding the masses of data that they were starting to produce." [03:45]

The team identified limitations in existing pre-implantation testing methods and sought to develop a more accurate and reliable solution. Chitra Kothwaliwale, Senior VP of Portfolio Management and Operations, underscores the technical challenges:

"Assessing the genetic health of the embryo starting with a single cell is extremely technically challenging." [07:20]

4. Development and Launch of Spectrum

Natera's breakthrough came with the development of Spectrum, a pre-implantation genetic test. Matthew Rabinowitz explains the innovative approach:

"We could structure it as a kind of a Bayesian optimization framework... a much more powerful test statistic." [08:02]

Jonathan Sheena elaborates on enhancing signal quality by leveraging parental genetic information:

"Knowing mom and dad... dramatically improved the signal out of the very noisy data." [08:53]

In 2009, Spectrum was launched, marking a significant milestone:

"In 2009, Natera launched the Spectrum test for public use." [14:41]

5. Initial Market Struggles and Pivot to Prenatal Testing

Despite the technical success of Spectrum, Natera faced commercial challenges:

"There was concern about the volume... the market wasn't deep enough to build a very big business." [15:49]

Recognizing the limitations of the IVF market, Matthew Rabinowitz made the pivotal decision to pivot towards natural pregnancies, leading to the development of Panorama, a non-invasive prenatal test (NIPT).

6. Launch and Success of Panorama

Steve Chapman, CEO of Natera, recounts the excitement around Panorama:

"There was no question that we were going to move forward with Panorama if the technology could deliver the results." [25:44]

Panorama revolutionized prenatal testing by offering more accurate and comprehensive genetic screening, significantly reducing false positives and unnecessary invasive procedures. Chitra Kothwaliwale highlights the impact:

"Processing over a million samples a year... other genetic testing for women's health markets." [33:36]

7. Expansion into Oncology

Buoyed by Panorama's success, Natera ventured into oncology with Signatera, a test for cancer recurrence monitoring. Matthew Rabinowitz describes the innovation:

"We could run all of these primers in a single reaction... detect cancers early, like finding one blade of grass in a hundred thousand soccer fields." [37:37]

Despite skepticism from investors and the challenges of entering a competitive market dominated by established players like Illumina and Roche, Natera persevered, driven by its mission and technological prowess.

8. Overcoming Adversity and Achieving Market Leadership

The journey was fraught with financial pressures and market skepticism. Matthew Rabinowitz admits:

"I was curled up in the corner of my living room... I didn't know how we were going to survive." [28:14]

However, the team's resilience and unwavering belief in their mission led to significant breakthroughs. Chitra Kothwaliwale reflects on the company's collaborative spirit:

"Unified vision... strong bonds among the people at Natera." [44:27]

By 2015, Natera went public, and subsequent years saw exponential growth in both the women's health and oncology divisions.

9. Current Success and Future Prospects

As of 2024, Natera stands as a market leader in both women's health and oncology genetic testing:

"Panorama is now the most widely used prenatal test in America... the share price has risen to well over $100." [47:55]

Matthew Rabinowitz envisions continued growth:

"There's another order of magnitude growth for Natera... using AI technology to model people's susceptibility to disease." [48:16]

Chitra Kothwaliwale emphasizes ongoing innovation:

"The innovative and agile spirit that we had five or 10 years ago cannot go away." [49:21]

10. Key Lessons and Conclusions

The narrative of Natera offers several key insights:

• Mission-Driven Leadership: Personal experiences can fuel entrepreneurial passion and drive transformative innovation.
• Resilience in the Face of Adversity: Navigating market challenges requires unwavering belief and adaptability.
• Collaborative Culture: A unified vision fosters collaboration and overcomes resource constraints.
• Continuous Innovation: Maintaining agility and a commitment to innovation ensures sustained market leadership.

Matthew Rabinowitz concludes with a heartfelt reflection:

"Bless the obstacle... if you're persistent and the science doesn't lie, it's very likely that you are going to find your path through." [51:15]

Notable Quotes with Timestamps

• Matthew Rabinowitz [00:02]:

  "Ever since I came to the States, I was kind of invincible... this just broke me."

• Roelof Botha [00:23]:

  "Natera is a company that has innovated again and again to change the management of disease worldwide."

• Jonathan Sheena [05:15]:

  "Geneticists needed help understanding the masses of data that they were starting to produce."

• Chitra Kothwaliwale [07:20]:

  "Assessing the genetic health of the embryo starting with a single cell is extremely technically challenging."

• Matthew Rabinowitz [08:02]:

  "We could structure it as a kind of a Bayesian optimization framework... a much more powerful test statistic."

• Steve Chapman [16:14]:

  "There are concerns expressed about the volume. We're having 90 tests a month."

• Sarah Elliott [32:14]:

  "Faces of families... helping them grow their family... a critical chapter for Natera."

• Matthew Rabinowitz [44:27]:

  "Bless the obstacle... if you're persistent and the science doesn't lie, it's very likely that you are going to find your path through."

Conclusion

Natera's journey, as detailed in this episode of Crucible Moments, is a testament to how personal passion, combined with technological innovation and unwavering commitment, can lead to groundbreaking advancements in healthcare. From overcoming initial skepticism to achieving market leadership in genetic testing, Natera's story serves as an inspiring blueprint for mission-driven entrepreneurship in the biotech industry.